You are here

Implantable construct for architectural control of re-vascularization of ischemic

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL118851-01
Agency Tracking Number: R41HL118851
Amount: $189,058.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3160 CHESTNUT ST STE 200
PHILADELPHIA, PA 19104-
United States
DUNS: 78270582
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL YANG
 (215) 746-1750
 myang@innolign.com
Business Contact
 MELINDA SHOCKLEY
Phone: (609) 571-6012
Email: mshockley@innolign.com
Research Institution
 TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
 
Office of Research Services 3451 Walnut Street P-221 Franklin Building
PHILADELPHIA, PA 19104-
United States

 () -
 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): Innolign Biomedical has developed an implantable product using novel tissue engineering technologies that spatially direct vascularization and will use the product in the treatment of ischemic conditions. The goal of this Phase I STTR proposal is to establish the feasibility of using this novel templated biomaterial, termed MicroBridge, to treat cardiac ischemia. More than 20 million Americans suffer from the ischemic heart disease with an estimated cost burden surpassing 60 billion annually. Despite substantial progress in angioplasty and bypass surgery to rescue perfusion to the coronary circulation, ischemic heart disease remains the leading cause of mortality and morbidity. MicroBridge will serve as an adjunct delivered during coronary artery bypass surgery that would direct vascularization in the microvasculature to reperfuse regions of ischemia not reached by large artery bypass alone. The product consists of pre- specified architectures of networks of aligned cordsof endothelial cells and matrix within a biodegradable implant. Upon implantation, the architectural template of MicroBridge guides new vessels to rapidly grow from a well perfused region to an ischemic region. The goal of Aim 1 is to test the capabilityof the MicroBridge product to vascularize and reperfuse ischemic tissue in an animal model of cardiac ischemia. The goal of Aim 2 is to establish the stability of the MicroBridge product under specific storage conditions. These studies will set the stage for further development of the MicroBridge product as a treatment for cardiac ischemia. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Reduced or lost blood flow to the heart is a leading cause of death and disease in the developed world. Thisproject is a feasibility study of a new tissue engineered product to treat cardiac ischemia by inducing the formation of new blood vessels that can provide additional paths for blood to reach the ischemic tissue.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government